Statistically Significant and Clinically Meaningful BATURA Phase III Trial Results Provide New Evidence for AIRSUPRA as Standard of Care for As-needed Rescue Treatment in Asthma
May 19, 2025
May 19, 2025
WILMINGTON, Delaware, May 19 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone
Positive full results from the BATUR . . .
* * *
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone
Positive full results from the BATUR . . .